Answers are grounded in this paper and cite their sources.
Background: Pleural mesothelioma (PM) is a rare cancer that is commonly associated with asbestos exposure. Due to its diffuse and distinct dispersion in the pleura, an R0 resection is hard and the prognosis bad. Recently, checkpoint inhibitors showed an extension of overall survival (OS) in unresectable PM, but a high unmet medical need for effective treatment remains. Tumor Treating Fields (TTFields) are low-intensity, intermediate frequency alternating electric fields that inhibit cancer cell division. In a phase 2 study (STELLAR), adding TTFields to pemetrexed plus cisplatin or carboplatin yielded encouraging results regarding median OS and progression-free survival. There is interest among prescribing physicians to validate these results in routine clinical care. The aim of this study is to evaluate safety and efficacy of TTFields in routine clinical care of PM, as well as changes in quality of life (QoL), treatment duration and device usage.
No takes yet. Share an insight, caveat, or question.
Metzenmacher et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: